High-dimensional in situ proteomics imaging to assess γδ T cells in spatial biology.

Cells: T Lymphocytes General: Adaptive Immunity General: Cancer General: Oncology Techniques: Proteomics

Journal

Journal of leukocyte biology
ISSN: 1938-3673
Titre abrégé: J Leukoc Biol
Pays: England
ID NLM: 8405628

Informations de publication

Date de publication:
29 Jan 2024
Historique:
received: 15 04 2023
revised: 19 12 2023
accepted: 21 12 2023
medline: 29 1 2024
pubmed: 29 1 2024
entrez: 29 1 2024
Statut: aheadofprint

Résumé

This study presents a high-dimensional immunohistochemistry approach to assess human γδ T cell subsets in their native tissue microenvironments at spatial resolution, a hitherto unmet scientific goal due to the lack of established antibodies and required technology. We report an integrated approach based on multiplexed imaging and bioinformatic analysis to identify γδ T cells, characterize their phenotypes, and analyze the composition of their microenvironment. Twenty-eight γδ T cell microenvironments were identified in tissue samples from fresh frozen human colon and colorectal cancer where interaction partners of the immune system but also cancer cells were discovered in close proximity to γδ T cells, visualizing their potential contributions to cancer immunosurveillance. While this proof-of-principle study demonstrates the potential of this cutting-edge technology to assess γδ T cell heterogeneity and to investigate their microenvironment, future comprehensive studies are warranted to associate phenotypes and microenvironment profiles with features such as relevant clinical characteristics.

Identifiants

pubmed: 38285597
pii: 7591289
doi: 10.1093/jleuko/qiad167
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of Society for Leukocyte Biology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Nicola Herold (N)

Department of Internal Medicine I, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
M3 Research Center for Malignome, Metabolome and Microbiome, Faculty of Medicine University Tübingen; Tübingen, Germany.

Matthias Bruhns (M)

Department of Internal Medicine I, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
M3 Research Center for Malignome, Metabolome and Microbiome, Faculty of Medicine University Tübingen; Tübingen, Germany.
Department of Computer Science, Eberhard Karls University of Tübingen, Tübingen, Germany.
Institute of Biomedical Informatics, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.

Sepideh Babaei (S)

Department of Internal Medicine I, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
M3 Research Center for Malignome, Metabolome and Microbiome, Faculty of Medicine University Tübingen; Tübingen, Germany.
Department of Computer Science, Eberhard Karls University of Tübingen, Tübingen, Germany.
Institute of Biomedical Informatics, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.

Janine Spreuer (J)

Department of Internal Medicine I, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
M3 Research Center for Malignome, Metabolome and Microbiome, Faculty of Medicine University Tübingen; Tübingen, Germany.

Arianna Castagna (A)

Department of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany.

Can Yurttas (C)

Department of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany.

Sophia Scheuermann (S)

Department of Pediatric Hematology and Oncology, University Hospital Tübingen, Tübingen, Germany.
Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies" Tübingen, Germany.

Christian Seitz (C)

Department of Pediatric Hematology and Oncology, University Hospital Tübingen, Tübingen, Germany.
Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies" Tübingen, Germany.

Benjamin Ruf (B)

Department of Internal Medicine I, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
M3 Research Center for Malignome, Metabolome and Microbiome, Faculty of Medicine University Tübingen; Tübingen, Germany.
Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies" Tübingen, Germany.

Alfred Königsrainer (A)

Department of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany.

Philipp Jurmeister (P)

Institute of Pathology, Ludwig Maximilians University Hospital Munich, Munich, Germany.
German Cancer Consortium (DKTK), Partner Site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Markus W Löffler (MW)

Department of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany.
Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies" Tübingen, Germany.
Department of Immunology, Interfaculty Institute for Cell Biology, Eberhard Karls University Tübingen, Tübingen, Germany.
Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tübingen, University Hospital Tübingen, Tübingen, Germany.
German Cancer Consortium (DKTK), Partner Site Tübingen, and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Manfred Claassen (M)

Department of Internal Medicine I, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
M3 Research Center for Malignome, Metabolome and Microbiome, Faculty of Medicine University Tübingen; Tübingen, Germany.
Department of Computer Science, Eberhard Karls University of Tübingen, Tübingen, Germany.
Institute of Biomedical Informatics, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.

Kilian Wistuba-Hamprecht (K)

Department of Internal Medicine I, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
M3 Research Center for Malignome, Metabolome and Microbiome, Faculty of Medicine University Tübingen; Tübingen, Germany.
Department of Immunology, Interfaculty Institute for Cell Biology, Eberhard Karls University Tübingen, Tübingen, Germany.
German Cancer Consortium (DKTK), Partner Site Tübingen, and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Classifications MeSH